5,100 Shares in TransMedics Group, Inc. (NASDAQ:TMDX) Acquired by Allianz Asset Management GmbH

Key Points

• Allianz Asset Management GmbH acquired 5,100 shares of TransMedics Group, Inc. for approximately $343,000 during the 1st quarter, adding to the growing institutional interest in the company.
• TransMedics Group reported strong earnings results with a net margin of 13.49% and a 37.7% year-over-year revenue growth, surpassing analysts’ expectations.
• Despite recent insider selling, institutional investors continue to dominate ownership, holding 99.67% of TransMedics' stock.

Allianz Asset Management GmbH acquired a new position in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 5,100 shares of the company's stock, valued at approximately $343,000.

Several other institutional investors have also recently bought and sold shares of TMDX. NBC Securities Inc. bought a new position in TransMedics Group in the 1st quarter worth approximately $25,000. Atlas Capital Advisors Inc. acquired a new position in TransMedics Group in the fourth quarter valued at approximately $31,000. Hager Investment Management Services LLC lifted its holdings in TransMedics Group by 38.3% in the first quarter. Hager Investment Management Services LLC now owns 740 shares of the company's stock valued at $50,000 after buying an additional 205 shares during the period. CWM LLC lifted its holdings in TransMedics Group by 20.1% in the first quarter. CWM LLC now owns 925 shares of the company's stock valued at $62,000 after buying an additional 155 shares during the period. Finally, GAMMA Investing LLC lifted its holdings in TransMedics Group by 551.7% in the first quarter. GAMMA Investing LLC now owns 1,564 shares of the company's stock valued at $105,000 after buying an additional 1,324 shares during the period. Institutional investors own 99.67% of the company's stock.

TransMedics Group Trading Up 1.3%

TMDX opened at $120.55 on Monday. The firm's fifty day moving average is $124.51 and its two-hundred day moving average is $95.50. The company has a debt-to-equity ratio of 1.61, a quick ratio of 9.17 and a current ratio of 9.86. The firm has a market cap of $4.11 billion, a PE ratio of 62.46 and a beta of 2.09. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $177.37.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.44. The company had revenue of $157.37 million for the quarter, compared to analyst estimates of $146.64 million. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The business's revenue for the quarter was up 37.7% compared to the same quarter last year. During the same period last year, the business posted $0.35 earnings per share. Equities research analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current year.

Insider Transactions at TransMedics Group

In other news, Director Edward M. Basile sold 5,000 shares of the stock in a transaction on Tuesday, May 27th. The shares were sold at an average price of $126.45, for a total transaction of $632,250.00. Following the completion of the sale, the director owned 2,866 shares of the company's stock, valued at $362,405.70. This represents a 63.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director David Weill sold 732 shares of the stock in a transaction on Friday, May 23rd. The stock was sold at an average price of $123.88, for a total transaction of $90,680.16. Following the sale, the director directly owned 12,134 shares of the company's stock, valued at $1,503,159.92. This represents a 5.69% decrease in their position. The disclosure for this sale can be found here. Insiders sold 12,418 shares of company stock valued at $1,512,613 over the last quarter. Corporate insiders own 7.00% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on TMDX. Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a report on Tuesday, June 17th. Oppenheimer increased their price objective on shares of TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a report on Tuesday, June 17th. Wall Street Zen upgraded shares of TransMedics Group from a "hold" rating to a "buy" rating in a report on Saturday. Canaccord Genuity Group increased their price objective on shares of TransMedics Group from $129.00 to $142.00 and gave the company a "buy" rating in a report on Tuesday, July 15th. Finally, Piper Sandler restated an "overweight" rating and issued a $145.00 price objective (up from $125.00) on shares of TransMedics Group in a report on Wednesday, June 4th. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $123.00.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.